Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00088452
Other study ID # U01NS045911
Secondary ID U01NS045803
Status Completed
Phase Phase 3
First received
Last updated
Start date July 2004
Est. completion date August 31, 2016

Study information

Verified date February 2017
Source Children's Hospital Medical Center, Cincinnati
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the best initial treatment for childhood absence epilepsy.


Description:

Childhood absence epilepsy (CAE) is a common pediatric epilepsy syndrome that affects 10 to 15 percent of all children with epilepsy. Individuals with CAE have brief staring spell seizures that occur suddenly, unpredictably, and frequently throughout the day. These seizures impair the children's ability to learn and play, and lead to higher injury rates.

There are many medications used to treat seizures, but only 3 generally are used as the first treatment for children with CAE: ethosuximide, lamotrigine, and valproic acid. The goal of this study is to determine which of these 3 medicines is the best first choice as treatment for children with CAE.

Approximately 439 children, recruited over a 3-year period at 32 medical centers in the US, will take part in this 5-year study. Participants will be randomly given one of the 3 common CAE treatments-ethosuximide, lamotrigine, or valproic acid-and will make regular visits to a clinic every 1 to 3 months for approximately 2 years. During the visits, participants will undergo regular testing to determine if the medicine is working, to watch for side effects, and to help researchers learn more about the responses to these medicines. In addition, researchers hope to develop methods that may be used in the future to help choose the best medicine for each individual diagnosed with CAE.

Also included in the study will be pharmacokinetics and pharmacogenetics research. Pharmacokinetics is the study of how the body absorbs, distributes, metabolizes, and excretes drugs. Pharmacogenetics is the study of genetic determinants of the response to drugs. Knowledge gained from this study may lead to individualized treatment for children with CAE, and may also be beneficial for other pediatric and adult seizure disorders.


Recruitment information / eligibility

Status Completed
Enrollment 453
Est. completion date August 31, 2016
Est. primary completion date January 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Months to 13 Years
Eligibility Inclusion Criteria:

- Diagnosis: Clinical diagnosis of Childhood Absence Epilepsy consistent with the International League against Epilepsy Proposal for Revised Classification of Epilepsies and Epileptic Syndromes (3).

- EEG: Interictal EEG demonstrating bilateral synchronous symmetrical approximate 3 Hz spike waves on a normal background with at least one burst lasting >/= (greater than or equal to) 3 seconds.

- Age > 2.5 years and < 13 years of age at study entry.

- Body weight >/= (greater than or equal to) 10 kilograms.

- Body Mass Index: BMI for age =/< 99th percentile (based on the CDC BMI for age growth curves for boys/girls [http://www.cdc.gov/growthcharts], Appendix 1).

- Hepatic:

- AST/ALT < 2.5 times the upper limit of normal

- Total bilirubin < 1.5 times the upper limit of normal.

- Hematologic:

- Absolute neutrophil count >/= (greater than or equal to) 1500/mm3.

- Platelets >/= (greater than or equal to) 120, 000 /mm3.

- Female subjects must be premenarchal at the time of enrollment and must be willing to practice abstinence for the duration of the study.

- Parent/legal guardian(s) willing to sign an IRB approved informed consent.

- Subject assent (when appropriate and as dictated by local IRB).

Exclusion Criteria:

- Treatment for CAE with anti-seizure medications (AED) for a period of greater than 7 days prior to randomization.

- History of a major psychiatric disease (e.g., psychosis, major depression).

- History of autism or pervasive development disorder.

- History of non-febrile seizures other than typical absence seizures. This includes a history of an afebrile generalized tonic clonic seizure.

- Clinical signs and symptoms consistent with a diagnosis of juvenile absence epilepsy or juvenile myoclonic epilepsy as delineated by the International League against Epilepsy Proposal for Revised Classification of Epilepsies and Epileptic Syndromes (3).

- History of recent or present significant or medical disease, i.e., cardiovascular, hepatic, renal, gynecologic, musculoskeletal, metabolic, or endocrine.

- History of a severe dermatologic reaction (e.g., Stevens Johnson, toxic epidermolysis necrosis) to medication.

- Subject or parent/legal guardian might not be reasonably expected to be compliant with or to complete the study.

- Participation in a trial of an investigational drug or device within 30 days prior to screening.

- Use of systemic contraceptive for any indication, including acne.

Study Design


Intervention

Drug:
Ethosuximide
Ethosuximide is a common treatment for childhood absence epilepsy.
Lamotrigine
Lamotrigine is a common treatment for childhood absence epilepsy.
Valproic acid
Valproic acid is a common treatment for childhood absence epilepsy.

Locations

Country Name City State
United States Children's Healthcare of Atlanta Atlanta Georgia
United States The Children's Hospital of Alabama Birmingham Alabama
United States Montefiore Medical Center Bronx New York
United States Women and Children's Hospital of Buffalo Buffalo New York
United States Children's Memorial Hospital Chicago Illinois
United States Cincinnati Children's Hospital Cincinnati Ohio
United States Rainbow Babies & Children's Hospital Cleveland Ohio
United States Children's Hospital, Inc., PCTI Columbus Ohio
United States Dallas Pediatric Neurology Associates Dallas Texas
United States Children's Hospital of Denver Denver Colorado
United States Children's Hospital of Michigan Detroit Michigan
United States Cook Children's Medical Center Fort Worth Texas
United States Texas Children's Hospital Houston Texas
United States Nemours Children's Clinic Jacksonville Florida
United States University of California at San Diego La Jolla California
United States Arkansas Children's Hospital Little Rock Arkansas
United States Mattel Children's Hospital at UCLA Los Angeles California
United States LeBonheur Children's Medical Center Memphis Tennessee
United States Miami Children's Hospital Miami Florida
United States Children's Hospital of Wisconsin Milwaukee Wisconsin
United States Yale University School of Medicine New Haven Connecticut
United States NYU Comprehensive Epilepsy Center, Manhattan New York New York
United States Children's Hospital of The King's Daughter (Monarch Medical Research) Norfolk Virginia
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania
United States St. Joseph's Hospital and Medical Center Phoenix Arizona
United States Children's Hospital of Pittsburgh Pittsburgh Pennsylvania
United States Doernbecher Children's Hospital Portland Oregon
United States Washington University in St. Louis Saint Louis Missouri
United States University of Utah/Primary Children's Medical Center Salt Lake City Utah
United States Children's Hospital & Regional Medical Center Seattle Washington
United States Children's National Medical Center Washington District of Columbia

Sponsors (2)

Lead Sponsor Collaborator
Children's Hospital Medical Center, Cincinnati National Institute of Neurological Disorders and Stroke (NINDS)

Country where clinical trial is conducted

United States, 

References & Publications (4)

Cnaan A, Shinnar S, Arya R, Adamson PC, Clark PO, Dlugos D, Hirtz DG, Masur D, Glauser TA; Childhood Absence Epilepsy Study Group. Second monotherapy in childhood absence epilepsy. Neurology. 2017 Jan 10;88(2):182-190. doi: 10.1212/WNL.0000000000003480. Epub 2016 Dec 16. — View Citation

Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Adamson PC; Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia. 2013 Jan;54(1):141-55. doi: 10.1111/epi.12028. Epub 2012 Nov 21. — View Citation

Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC; Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010 Mar 4;362(9):790-9. do — View Citation

Shinnar S, Cnaan A, Hu F, Clark P, Dlugos D, Hirtz DG, Masur D, Mizrahi EM, Moshé SL, Glauser TA; Childhood Absence Epilepsy Study Group. Long-term outcomes of generalized tonic-clonic seizures in a childhood absence epilepsy trial. Neurology. 2015 Sep 29;85(13):1108-14. doi: 10.1212/WNL.0000000000001971. Epub 2015 Aug 26. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy Treatment failure was defined as persistence of absence seizures at week 16 or week 20, a generalized tonic-clonic seizure at any time, excessive drug-related systemic toxicity, a moderately severe rash (possibly drug-related), pancreatitis, or increase in the body-mass index of at least 3.0 from baseline, dose-limiting toxicity after a single downward dose modification, or withdrawal initiated by the parent or physician. First 16-20 weeks of double blind therapy
Secondary Number of Participants With Attention Deficit as Measured by the Confidence Index of the CPT-II and the K-CPT A Confidence Index of 0.60 or higher on the Conners' Continuous Performance Test at the visit at 16 or 20 weeks or at an earlier visit when treatment was discontinued (as long as the discontinuation occurred 1 month or more after the baseline visit and was not due to intolerable adverse events). A Confidence Index of 0.60 corresponds to a 60% probability that the child has clinical attention deficit disorder. First 16-20 weeks of double blind therapy
Secondary Number of Participants With Freedom From Treatment Failure at 12 Months of Double Blind Therapy Treatment failure was defined as persistence of absence seizures at 12 months of double blind therapy, a generalized tonic-clonic seizure at any time, excessive drug-related systemic toxicity, a moderately severe rash (possibly drug-related), pancreatitis, or increase in the body-mass index of at least 3.0 from baseline, dose-limiting toxicity after a single downward dose modification, or withdrawal initiated by the parent or physician. First 12 months of double blind therapy
See also
  Status Clinical Trial Phase
Completed NCT04595513 - Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants Phase 1/Phase 2
Completed NCT02909387 - Adapting Project UPLIFT for Blacks in Georgia N/A
Completed NCT05552924 - Self Acupressure on Fatigue and Sleep Quality in Epilepsy Patients N/A
Terminated NCT01668654 - Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS Phase 3
Not yet recruiting NCT05068323 - Impact of Interictal Epileptiform Activity on Some Cognitive Domains in Newly Diagnosed Epileptic Patients N/A
Completed NCT03994718 - Creative Arts II Study N/A
Recruiting NCT04076449 - Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
Completed NCT00782249 - Trial Comparing Different Stimulation Paradigms in Patients Treated With Vagus Nerve Stimulation for Refractory Epilepsy N/A
Completed NCT03683381 - App-based Intervention for Treating Insomnia Among Patients With Epilepsy N/A
Recruiting NCT05101161 - Neurofeedback Using Implanted Deep Brain Stimulation Electrodes N/A
Active, not recruiting NCT06034353 - Impact of Pharmacist-led Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients N/A
Recruiting NCT05769933 - Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
Not yet recruiting NCT06408428 - Glioma Intraoperative MicroElectroCorticoGraphy N/A
Not yet recruiting NCT05559060 - Comorbidities of Epilepsy(Cognitive and Psychiatric Dysfunction)
Completed NCT02646631 - Behavioral and Educational Tools to Improve Epilepsy Care N/A
Completed NCT02952456 - Phenomenological Approach of Epilepsy in Patients With Epilepsy
Completed NCT02977208 - Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use Phase 4
Recruiting NCT02539134 - TAK-935 Multiple Rising Dose Study in Healthy Participants Phase 1
Terminated NCT02757547 - Transcranial Magnetic Stimulation for Epilepsy N/A
Completed NCT02491073 - Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL) N/A